S J McMillan1, G Xanthou, C M Lloyd. 1. Leukocyte Biology Section, Division of Biomedical Sciences, Faculty of Medicine Imperial College, London SW7 2AZ, UK.
Abstract
BACKGROUND: Airway inflammation and remodelling are important pathophysiologic features of chronic asthma. Although current steroid use demonstrates anti-inflammatory activity, there are limited effects on the structural changes in the lung tissue. OBJECTIVE: We have used a mouse model of prolonged allergen challenge that exhibits many of the salient features of airway remodelling in order to investigate the anti-remodelling effects of Budesonide. METHODS: Treatment was administered therapeutically, with dosing starting after the onset of established eosinophilic airway inflammation and hyper-reactivity. RESULTS: Budesonide administration reduced airway hyper-reactivity and leukocyte infiltration in association with a decrease in production of the Th2 mediators, IL-4, IL-13 and eotaxin-1. A reduction in peribronchiolar collagen deposition and mucus production was observed. Moreover, our data show for the first time that, Budesonide treatment regulated active transforming growth factor (TGF)-beta signalling with a reduction in the expression of pSmad 2 and the concomitant up-regulation of Smad 7 in lung tissue sections. CONCLUSIONS: Therefore, we have determined that administration of Budesonide modulates the progression of airway remodelling following prolonged allergen challenge via regulation of inflammation and active TGF-beta signalling.
BACKGROUND:Airway inflammation and remodelling are important pathophysiologic features of chronic asthma. Although current steroid use demonstrates anti-inflammatory activity, there are limited effects on the structural changes in the lung tissue. OBJECTIVE: We have used a mouse model of prolonged allergen challenge that exhibits many of the salient features of airway remodelling in order to investigate the anti-remodelling effects of Budesonide. METHODS: Treatment was administered therapeutically, with dosing starting after the onset of established eosinophilic airway inflammation and hyper-reactivity. RESULTS:Budesonide administration reduced airway hyper-reactivity and leukocyte infiltration in association with a decrease in production of the Th2 mediators, IL-4, IL-13 and eotaxin-1. A reduction in peribronchiolar collagen deposition and mucus production was observed. Moreover, our data show for the first time that, Budesonide treatment regulated active transforming growth factor (TGF)-beta signalling with a reduction in the expression of pSmad 2 and the concomitant up-regulation of Smad 7 in lung tissue sections. CONCLUSIONS: Therefore, we have determined that administration of Budesonide modulates the progression of airway remodelling following prolonged allergen challenge via regulation of inflammation and active TGF-beta signalling.
Authors: A Rosendahl; D Checchin; T E Fehniger; P ten Dijke; C H Heldin; P Sideras Journal: Am J Respir Cell Mol Biol Date: 2001-07 Impact factor: 6.914
Authors: I Ohno; Y Nitta; K Yamauchi; H Hoshi; M Honma; K Woolley; P O'Byrne; G Tamura; M Jordana; K Shirato Journal: Am J Respir Cell Mol Biol Date: 1996-09 Impact factor: 6.914
Authors: A Wallin; T Sandström; M Söderberg; P Howarth; B Lundbäck; G Della-Cioppa; S Wilson; M Judd; R Djukanović; S Holgate; A Lindberg; L Larssen; B Melander Journal: Am J Respir Crit Care Med Date: 1999-01 Impact factor: 21.405
Authors: Anna G Taranova; David Maldonado; Celine M Vachon; Elizabeth A Jacobsen; Hiam Abdala-Valencia; Michael P McGarry; Sergei I Ochkur; Cheryl A Protheroe; Alfred Doyle; Clive S Grant; Joan Cook-Mills; Lutz Birnbaumer; Nancy A Lee; James J Lee Journal: Cancer Res Date: 2008-10-15 Impact factor: 12.701
Authors: Aneta Tomkowicz; Maria Kraus-Filarska; Julia Bar; Jerzy Rabczyński; Michał Jeleń; Paweł Piesiak; Andrzej Fal; Bernard Panaszek Journal: Arch Immunol Ther Exp (Warsz) Date: 2008-12-01 Impact factor: 4.291